Advanced or Metastatic Non-small Cell Lung Cancer Clinical Trial
Official title:
A Randomized, Open-Label, Multi-Center, International Phase 2 Study of TAS-114 in Combination With S-1 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
This is a randomized, open-label, Phase 2 study of TAS-114 administered in combination with S-1, to investigate the efficacy, safety and tolerability of the TAS-114/S-1 regimen in patients with advanced or metastatic NSCLC. The study will be conducted internationally in 2 regions: Asian [Japan] and Western [Europe and US]. Patients will be randomized into TAS-114/S-1 arm versus S-1 control arm in a 1:1 ratio.
Randomization will take place once the consented patient has completed all the necessary baseline procedures and is deemed eligible for study entry. Treatment assignment will be done centrally using a dynamic allocation method (biased coin) via an interactive voice/web response system (IXRS) stratified by: - Geographical region (Region 1: Asian [Japan]; Region 2: Western [Europe and US]) - Histological subtypes (nonsquamous cell carcinoma [including mixed] and squamous cell carcinoma) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05450692 -
A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
|
Phase 3 | |
| Recruiting |
NCT05621525 -
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
|
Phase 1 | |
| Completed |
NCT00716534 -
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Active, not recruiting |
NCT05388669 -
A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 3 |